Pricing
Compounded vs Brand-Name GLP-1 Cost in 2026: An Honest Comparison
Released: · Last reviewed:
Different regulatory standing, different risk, different cost. Comparing them fairly means not ranking them together.
The single most common question in this category is whether compounded GLP-1s are cheaper than the brand-name products. The short answer is usually yes on cash price — but the comparison is more complicated than a price tag, because the two are different product classes with different regulatory standing.
What you're actually comparing
Brand-name Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved products that went through premarket review of manufacturing, safety, and effectiveness. Compounded semaglutide and tirzepatide are pharmacy-prepared products made with the drugs in Wegovy and Zepbound, not the same products, and they did not go through that review. This isn't a technicality: it means the trial evidence belongs to the approved products, quality assurance shifts to the individual compounding pharmacy, and the compounded product is not a generic. A fair comparison treats them as separate classes, which is why this site never ranks a compounded program against a brand product in one ordering.
The cash-price gap has narrowed
Two years ago the gap was enormous — brand list prices above $1,000/month versus compounded programs in the low hundreds. That gap has narrowed from both directions. Manufacturer cash-pay programs like LillyDirect and NovoCare now sell approved products at negotiated self-pay prices well below list. In our October 15, 2026 index, compounded semaglutide runs $49–$193.92 a month all-in at each program's lowest printed plan (median $97) and compounded tirzepatide $85.58–$449 (median $149), while LillyDirect sells Zepbound at $299 to $449 a month by dose and NovoCare sells the Wegovy pen at $349 and the Wegovy pill from $149. The result is a market where the honest comparison is closer than the old "hundreds versus thousands" framing suggests.
What the compounded discount buys — and costs
The compounded discount is real, but it comes with trade-offs that don't show up in the price. You gain a lower cash price and, often, a simpler telehealth experience. You give up premarket-reviewed manufacturing, the assurance that every unit matches a studied formulation, and — for oral or sublingual compounded products — any confidence that the drug is even absorbed. As the price gap narrows, those trade-offs weigh more heavily: paying $119 a month for compounded semaglutide instead of $149–$299 for the Wegovy pill or $349 for the Wegovy pen is a different calculation than paying $119 instead of $1,000.
Insurance changes everything, when it applies
For patients whose insurance covers a brand product, the comparison inverts. An insured copay for approved Zepbound can be cheaper than any cash-pay compounded program, with the added benefit of a reviewed product. Compounded medications are generally not covered by insurance, so they compete on cash price against other cash options — not against an insured copay. The first question for anyone with coverage is whether the approved product is covered before compounded pricing is even relevant.
A structured way to decide
Price the options as separate columns rather than a single ranking. Column one: your insured cost for an approved product, if covered. Column two: manufacturer cash-pay for an approved product (LillyDirect, NovoCare). Column three: compounded cash price at your maintenance dose, normalized to effective monthly cost. Then weigh regulatory standing, pharmacy verifiability, and your prescriber's judgment alongside price. The cheapest column and the right column are frequently not the same, and only you and a clinician can make that call.
Why we keep the classes separate
It would be easy — and misleading — to publish a single "cheapest GLP-1" table mixing compounded and brand products. That table would imply the products are interchangeable on everything but price, which they aren't. Regulatory standing is a real difference a price column can't capture. Keeping the classes separate is less convenient but more honest, and it's the same discipline that keeps us from crowning a "most affordable" compounded winner before the evidence supports it. See the brand-vs-compounded cost guide for the detailed breakdown.
Current compounded pricing for context
Both tables below were read on October 15, 2026. Compounded figures are each program's lowest printed all-in monthly price, required memberships included; the full program-by-program tables, sorted low to high, are on the semaglutide and tirzepatide pages.
| Measure | Semaglutide | Tirzepatide | Basis |
|---|---|---|---|
| Programs priced | 24 | 31 | programs printing a comparable per-drug price |
| Range, all-in low | $49–$193.92 | $85.58–$449 | lowest figures are sale, "from", prepaid or membership-dependent prices |
| Median, all-in low | $99 | $149 | median of the programs above |
| Lowest standing month-to-month, no membership | $87 (Mondae) | $126 (Mondae) | no sale, no membership; mondae.com |
| NexLife (#1 overall) | $109 m-t-m; $95 on 12 months | $129 m-t-m; $115 on 12 months | same price at every dose, no membership; nexlife.us |
| Product | Self-pay price | Seller | Read |
|---|---|---|---|
| Zepbound (tirzepatide) vials | $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with each refill within 45 days; otherwise $499 at 7.5 mg, $699 at 10–15 mg) | LillyDirect (lilly.com) | on file 2026-10-15 |
| Wegovy (semaglutide) pen | $349 (0.25–2.4 mg); new patients $199 for two fills of 0.25/0.5 mg through Dec 31, 2026; Wegovy HD 7.2 mg $399 | NovoCare (novocare.com) | 2026-10-15 |
| Wegovy (semaglutide) pill | $149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg) | NovoCare (novocare.com) | 2026-10-15 |
| Foundayo | $149 (0.8 and 2.5 mg) and $199 (5.5 mg) temporarily through Dec 31, 2026; $299 (9 mg); $299 (14.5/17.2 mg with 45-day refills; regular $349) | LillyDirect (lilly.com) | archived pages dated 2026-09-25 |
Compounded prices as printed on each program's own page on October 15, 2026, not checkout-verified. Compounded tirzepatide and semaglutide are not FDA-approved. Brand and manufacturer cash-pay prices are a separate class and are never ranked against these figures.
Frequently asked questions
Is compounded semaglutide the same as Ozempic or Wegovy?
No. It is made with the drug in Ozempic and Wegovy, but it is not the same product: it is a pharmacy-prepared product that wasn't reviewed by FDA and isn't a generic. The approved products carry premarket-reviewed manufacturing that compounded products don't. They're different product classes, which is why this site never ranks them together.
Will insurance cover a compounded GLP-1?
Rarely. Compounded medications are generally not covered, so they compete on cash price against other cash options — including manufacturer cash-pay programs for the approved products. If you have insurance coverage for an approved product, that's usually the first thing to price, since an insured copay can beat any cash compounded price.
As the price gap narrows, is compounded still worth it?
It depends on your alternatives. Paying $119 compounded instead of $1,000 brand is a very different decision from paying $119 compounded instead of $149–$349 manufacturer cash-pay for a reviewed product (NovoCare's Wegovy pill and pen prices on October 15, 2026). As the gap narrows, the regulatory and quality trade-offs weigh more heavily, and the answer becomes more individual — a conversation for you and a clinician.
The bottom line
Compounded GLP-1s are usually cheaper on cash price than brand products, but the gap has narrowed and the products aren't equivalent. If you have insurance coverage for an approved product, price that first. If you're paying cash, compare compounded effective monthly cost against manufacturer cash-pay programs as separate options, and factor in the regulatory and quality differences that price alone won't show.